China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced receiving approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its HS-10517, a Category 1 anti-COVID-19 drug co-developed by the Global Health Drug Discovery Institute (GHDDI). The study will focus on mild to moderate COVID-19 adult patients, marking a significant step in the development of this novel therapy.
HS-10517: Mechanism and Development
HS-10517 is a 3CL protease inhibitor that has demonstrated anti-viral activity against both the Delta and Omicron variants of SARS-CoV-2. The drug is the subject of an RMB 1.692 billion (USD 249.48 million) licensing deal signed in August 2022, granting Hansoh exclusive global rights to the product. This approval positions HS-10517 as a potential new treatment option for COVID-19, particularly targeting patients with mild to moderate symptoms.
GHDDI Background
The Global Health Drug Discovery Institute (GHDDI) is an independently operated, non-profit, innovative drug research and development institution. It was jointly founded by the Bill & Melinda Gates Foundation, Tsinghua University, and the Beijing Municipal Government. GHDDI’s mission is to accelerate the discovery and development of novel drugs for global health challenges, making it a key partner in the fight against COVID-19.
Future Outlook
With NMPA approval for clinical studies, Hansoh is poised to advance HS-10517 through its development pipeline. This collaboration with GHDDI underscores Hansoh’s commitment to addressing significant unmet medical needs and contributing to global efforts to combat COVID-19.-Fineline Info & Tech
